Recent Updates
Recently added Catalysts
ELDN Positive Sentiment

Eledon unveils first evidence of insulin independence in tegoprubart-treated islet transplants

Key Takeaway: Eledon has announced the first evidence of insulin independence in patients receiving islet transplants treated with tegoprubart. This breakthrough suggests that tegoprubart may enhance the effectiveness of islet transplants, offering new hope for patients with diabetes. The findings could significantly impact future treatment protocols and patient outcomes.
Price reaction · baseline $2.62 (2024-10-04 close) · 7 other ELDN headline(s) in the window, move may be shared
day 0 close
0%

Market Sentiment Analysis

POSITIVE FACTORS

  • First evidence of insulin independence in islet transplants.
  • Tegoprubart shows promising results in clinical applications.
  • Potential to transform lives through improved transplant outcomes.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+90%
120-day peak, hindsight
Typical move
6.5%
average across 7 past catalysts
Cash runway
~11 mo
Medium dilution risk
Lead asset
AT-1501
Phase 2 · Kidney Transplant Rejection

Full Press Release Details

Transforming Lives. One Organ at a Time.
• Overview Focus Patient Stories Clinical Trials In The News
• Science Mechanism of Action Pipeline Publications & Presentations In The News
• Team Overview Leadership Board of Directors
• Investors Overview News & Events Press Releases Events Publications & Presentations Corporate Governance Governance Overview Committee Composition Ethics Hotline Financials SEC Filings Stock Information Stock Quote & Chart Analyst Coverage Resources Investor FAQs Email Alerts Contact IR
• Culture/Careers Culture Careers
• Contact
• Focus
• Patient Stories
• Clinical Trials
• In The News
• Mechanism of Action
• Pipeline
• Publications & Presentations
• In The News
• Overview
• Leadership
• Board of Directors
• Overview
• News & Events Press Releases Events Publications & Presentations
• Corporate Governance Governance Overview Committee Composition Ethics Hotline
• Financials SEC Filings
• Stock Information Stock Quote & Chart Analyst Coverage
• Resources Investor FAQs Email Alerts Contact IR
• Press Releases
• Events
• Publications & Presentations
• Governance Overview
• Committee Composition
• Ethics Hotline
• SEC Filings
• Stock Quote & Chart
• Analyst Coverage
• Investor FAQs
• Email Alerts
• Contact IR
• Culture
• Careers
• Privacy Overview
• Necessary
• Analytics
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.
This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.
Keeping this cookie enabled helps us to improve our website.

Frequently Asked Questions

What is tegoprubart?

Tegoprubart is a treatment being studied for its potential to improve islet transplant outcomes.

What does insulin independence mean?

Insulin independence refers to the ability of patients to maintain normal blood sugar levels without insulin injections.

How does tegoprubart affect islet transplants?

Tegoprubart has shown promising results in enhancing the effectiveness of islet transplants.

What are the implications of this breakthrough?

This breakthrough could significantly improve treatment protocols and patient outcomes in diabetes care.

Last updated: Oct 6, 2024